Clinical Trial Update: SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SBRT in combination with durvalumab for inoperable/unresectable hepatocellular carcinoma is ongoing; status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• SBRT (stereotactic body radiotherapy)

Snippet

Sponsor: The University of Hong Kong | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN